Based on peer comps EYE should already be at about 60c (even...

Based on peer comps EYE should already be at about 60c (even without iTrack Advance FDA clearance and the exponential revenue growth). Peer revenue multiples are about 4-6x and we are just 2x LTM revenue. The share price is still incredibly cheap for the revenue currently being generated and the potential for 2RT to be the first ever treatment for one of the leading causes of blindness. The company has already proved iTrack Advance can deliver strong revenue growth in the markets it is already cleared in, so the fact that the price hasn't re-rated yet to a 4-6x revenue multiple beats me. This is all without considering the future revenue that iTrack Advance will deliver. iTrack Advance will enter a massive and fast-growing market with features that are (imo) superior to those of competitors. The revenue potential here could be enormous. Package all that with a few positive announcements re 2RT progress and we could easily be looking at a share price in the dollars (in the near term as well).